Accelerating research

and development of

new antibiotics and

alternatives

News

NADP News

World Antibiotics Awareness Week

17 November 2017

World Antibiotic Awareness Week

The week of 13 -19 November 2017 is World Antibiotic Awareness Week! The World Antibiotic Awareness Week is an initiative of the WHO to spread awareness on risks and prevention of antibiotic resistance. For this occasion, an expert panel from the European Academy of Microbiology (EAM) discusses what the future holds for antimicrobial resistance (AMR) and what can be done to actively tackle it.

Read more

WHO: stop using antibiotics in healthy animals to prevent the spread of antibiotic resistance

8 November 2017

WHO is recommending that farmers and the food industry stop using antibiotics routinely to promote growth and prevent disease in healthy animals.

The new WHO recommendations aim to help preserve the effectiveness of antibiotics that are important for human medicine by reducing their unnecessary use in animals. In some countries, approximately 80% of total consumption of medically important antibiotics is in the animal sector, largely for growth promotion in healthy animals.

Read more

Prof. Marc Bonten reacts on use of bacteriophage against AMR

25 October 2017

Prof. Marc Bonten, chairman of the focus area Infection & Immunity at UMC Utrecht, and board member of NADP, wrote a blog on the use of bacteriophages to treat infections caused by resistant bacteria.

Read more

WHO published report on antibacterial agents in clinical development

21 September 2017

As part of implementation of the Global Action Plan on Antimicrobial Resistance, WHO drew up a list of priority antibiotic-resistant pathogens (priority pathogens list; PPL) to guide research into and the discovery and development of new antibiotics. Furthermore, the pipeline of antibacterial products that are in clinical development was analyzed.

Read more

British Biotech Receives €52M Boost to Beat Antimicrobial Resistance with New Antibiotic

13 September 2017

In a recent press release Summit Therapeutics announced they received the BARDA Contract worth $62 mil. for the development of a new treatment against Clostridium difficile infections.

Read more

Events Calendar

Upcoming events

A list of upcoming events, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.

Read More